Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase RNF20 (RNF20)
- Target
- RNF20
- Molecular classification
- Enzyme, E3 ubiquitin ligase, RING finger protein, Histone modification
01
Overview
E3 ubiquitin-protein ligase RNF20 is a RING finger E3 ligase that primarily forms a complex with RNF40 to monoubiquitinate histone H2B at lysine 120. This modification serves as a key epigenetic marker that facilitates gene transcription and is prerequisite for further histone methylation at H3K4 and H3K79. RNF20 plays critical roles in regulating chromatin structure, DNA repair, and tumor suppression by activating p53 as well as controlling the expression of multiple histone and non-histone genes. It acts as a tumor suppressor but can also repress certain protooncogenes. RNF20 is implicated in maintaining genomic stability, modulating metabolic pathways in adipose tissue, and has been associated with various diseases including cancer, metabolic syndromes, and certain viral infections. No drugs are directly known to target RNF20 at this time, but it is a potential therapeutic target for diseases related to epigenetic dysregulation and cancer[1][2][4][5][7].
- Other names
- Ring finger protein 20BRE1ABRE1-AhBRE1RING-type E3 ubiquitin transferase BRE1AFLJ20382FLJ11189KAIA2779BRE1BRE1A E3 ubiquitin ligase homolog (S. cerevisiae)RING finger protein 20, homolog of S. cerevisiae BRE1
02
Mechanism of action
Indirect: drugs affecting the ubiquitin-proteasome pathway can influence RNF20 activity, but no RNF20-specific pharmacological agents are known.
03
Biological functions
Histone monoubiquitination (especially H2B at lysine 120)Epigenetic transcriptional regulationChromatin remodelingDNA damage response and double-strand break repairRegulation of p53 tumor suppressor activityRegulation of gene expression (suppressing protooncogenes and growth-related genes)Adipose tissue thermogenesis regulation
04
Disease associations
Cancer (as a tumor suppressor and in chromatin instability)Metabolic diseases (adipose tissue function, obesity/metabolism)Human herpesvirus 8 infectionDesanto-Shinawi syndrome
05
Safety considerations
Potential genomic instability if inhibited or lostEffects on global epigenetic regulation and transcriptionImpact on tumor suppression and risk of oncogenesis when dysregulated
06
Biomarkers
RNF20/H2Bub1 status (for cancer prognosis or chromatin modification assessment)p53 and its downstream effectors (context-dependent, for tumorigenesis and DNA damage response)
Beyond the preview
Go deeper on E3 ubiquitin-protein ligase RNF20 (RNF20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E3 ubiquitin-protein ligase RNF20 (RNF20).